[Translation] A Phase Ib clinical study of the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of HS-20117 combination therapy in patients with advanced solid tumor cancers
主要研究目的
1. 评价HS-20117联合治疗在晚期实体瘤患者中的安全性和耐受性。
次要研究目的
1. 评价HS-20117联合治疗在晚期实体瘤患者的有效性。
2. 评价HS-20117联合治疗在晚期实体瘤患者的药代动力学(PK)特征。
3. 评价HS-20117联合治疗在晚期实体瘤患者的免疫原性(ADA)。
[Translation] Main study objectives
1. To evaluate the safety and tolerability of HS-20117 combination therapy in patients with advanced solid tumors.
Secondary study objectives
1. To evaluate the efficacy of HS-20117 combination therapy in patients with advanced solid tumors.
2. To evaluate the pharmacokinetic (PK) characteristics of HS-20117 combination therapy in patients with advanced solid tumors.
3. To evaluate the immunogenicity (ADA) of HS-20117 combination therapy in patients with advanced solid tumors.